In this blog, #HannahSyed highlights how NHS Sussex switched thousands of eligible patients from SGLT2 inhibitors to generic dapagliflozin without compromising on safety or clinical credibility — and achieved a £2.5m net annual saving
@pharmaj.bsky.social